newsfilter
← Latest News
Business Wire·

bioAffinity Technologies Announces Pricing of $3.2 Million Offering

BIAFBIAFW
  • bioAffinity Technologies, Inc. priced a public offering for aggregate gross proceeds of $3.2 million before fees & expenses.
  • The offering consists of 4,000,000 shares of common stock or pre-funded warrants at $0.80 per share or $0.793 per warrant.
  • Closing of the offering is expected on or about June 18, 2026, subject to customary conditions.
  • WallachBeth Capital, LLC is acting as the sole placement agent for the transaction.
  • The securities are offered pursuant to an SEC-effective Form S-1 registration statement.
  • CyPath® Lung is a noninvasive LDT using flow cytometry & AI to detect early-stage lung cancer in high-risk patients.
  • Clinical trials showed CyPath® Lung achieved 92% sensitivity, 87% specificity, 88% accuracy, & 99% negative predictive value.
  • The test is marketed as a Laboratory Developed Test under CLIA oversight by Precision Pathology Laboratory Services.
  • Forward-looking statements in the release are subject to risks that could cause actual results to differ from expectations.